Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure.

Eur J Heart Fail · 2020 · PMC7540031 · PMID 32452085

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The 18% nominally significant risk reduction of the primary outcome in the Americas has encouraged societies in the US to believe that, if properly implemented, spironolactone may improve outcomes in patients with HFpEF. 9 In HFpEF patients with resistant hypertension from the Americas enrolled in TOPCAT, a post hoc analysi

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.